ROCKVILLE, Md., April 26, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointments of Louis Fries III, M.D., as Vice President, Clinical and Medical Affairs, and Jane Halpern, Ph.D., as Vice President of Regulatory Affairs. Before joining Novavax, Dr. Fries was Director, Global Clinical Development at GSK Biologicals, North America and Dr. Halpern was Staff Scientist and Regulatory Affairs Specialist at the Vaccine Research Center of the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health.
"We are excited to welcome these two highly talented senior executives to our company," said Gregory Glenn, M.D., Novavax's Senior Vice President and Chief Medical Officer. "Each brings extensive experience in the development, clinical testing and registration of influenza and novel vaccines and more than two decades of industry and government experience. Their appointments are timely as we turn our attention to late-stage clinical development and commercialization of our virus-like-particle vaccines to prevent the spread of seasonal and pandemic influenza."
Stanley Erck, President and CEO of Novavax, added: "These appointments reflect our commitment to strengthening the Novavax management team as we work to advance and commercialize our VLP technology worldwide. Lou and Jane possess the requisite managerial, medical and scientific skills to guide our vaccine development programs at a critical stage in our company's history. We welcome their contributions to our future success."
Previously, Dr. Fries was Vice President, Clinical and Medical Affairs, at ID Biomedical Corp. (acquired by GSK in 2005) and Senior Director, Clinical Research at NABI. He is board-certified in internal medicine and infectious diseases and received his medical degree from Duke University School of Medicine.Dr. Halpern has served as Vice President, Regulatory Affairs, at Genocea Biosciences, Director of Regulatory Affairs and Head, Technical Regulatory Affairs, North America at GSK Biologicals, and Vice President of Global Regulatory Affairs at ID Biomedical, and held a variety of regulatory affairs and staff positions with the NIAID and the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration. She received her doctor of philosophy degree in pharmacology from the University of Rochester. About Novavax Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company's proprietary VLP technology and single-use bioprocessing system enables rapid vaccine development and production where and when it's needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com. Forward Looking Statements Statements herein relating to the future of Novavax and its ongoing development of its VLP vaccine products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2010, and filed with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. SOURCE Novavax, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV